Arthur Martinet

Arthur Martinet

Auto-generated profile, based on publicly available information

Arthur Martinet

IGBMC

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TMThomas Di Mattia
Thomas Di Mattia
AMArthur Martinet
Arthur Martinet
SISouade Ikhlef
Souade Ikhlef
AMAlastair Graham McEwen
Alastair Graham McEwen
YNYves Nominé
Yves Nominé
FAFabien Alpy
Fabien Alpy
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

7 April 2022 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
MZMehdi Zouiouich
Mehdi Zouiouich
TMThomas Di Mattia
Thomas Di Mattia
AMArthur Martinet
Arthur Martinet
JEJulie Eichler
Julie Eichler
CWCorinne Wendling
Corinne Wendling
FAFabien Alpy
Fabien Alpy
Membrane contact sites between organelles are organized by protein bridges. Among the components of these contacts, the VAP family comprises ER–anchored proteins, such as MOSPD2, that function as major ER–organelle tethers. MOSPD2 distinguishes itself from the other members of the VAP family by the presence of a CRAL-TRIO domain. In this study, we show that MOSPD2 forms ER–lipid droplet (LD) contacts, thanks to its CRAL-TRIO domain. MOSPD2 ensures the attachment of the ER to LDs through a direct protein–membrane interaction. The attachment mechanism involves an amphipathic helix that has an affinity for lipid packing defects present at the surface of LDs. Remarkably, the absence of MOSPD2 markedly disturbs the assembly of lipid droplets. These data show that MOSPD2, in addition to being a general ER receptor for inter-organelle contacts, possesses an additional tethering activity and is specifically implicated in the biology of LDs via its CRAL-TRIO domain.

18 March 2024 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
SMShirish Mishra
Shirish Mishra
VMVaishnavi Manohar
Vaishnavi Manohar
SCShabnam Chandel
Shabnam Chandel
TMTejaswini Manoj
Tejaswini Manoj
SBSubhodeep Bhattacharya
Subhodeep Bhattacharya
PRPadinjat Raghu
Padinjat Raghu
Lipid transfer proteins mediate the transfer of lipids between organelle membranes, and the loss of function of these proteins has been linked to neurodegeneration. However, the mechanism by which loss of lipid transfer activity leads to neurodegeneration is not understood. InDrosophilaphotoreceptors, depletion of retinal degeneration B (RDGB), a phosphatidylinositol transfer protein, leads to defective phototransduction and retinal degeneration, but the mechanism by which loss of this activity leads to retinal degeneration is not understood. RDGB is localized to membrane contact sites through the interaction of its FFAT motif with the ER integral protein VAP. To identify regulators of RDGB function in vivo, we depleted more than 300 VAP-interacting proteins and identified a set of 52 suppressors ofrdgB. The molecular identity of these suppressors indicates a role of novel lipids in regulating RDGB function and of transcriptional and ubiquitination processes in mediating retinal degeneration inrdgB9. The human homologs of several of these molecules have been implicated in neurodevelopmental diseases underscoring the importance of VAP-mediated processes in these disorders.

22 September 2026 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
EPEvanthia Pangou
Evanthia Pangou
SASushil Awal
Sushil Awal
MMMathieu Meode
Mathieu Meode
CKCharlotte Kleiss
Charlotte Kleiss
MCMehdi Cloarec
Mehdi Cloarec
ISIzabela Sumara
Izabela Sumara
Cancer cells tolerate mitotic errors to sustain proliferation, yet the molecular dependencies enabling this tolerance remain poorly understood and largely unexploited therapeutically. UBASH3B ensures mitotic fidelity by regulating Aurora B localization and is overexpressed in tumors. We investigated whether pharmacological disruption of this pathway exposes a mitotic dependency in cancer. We demonstrate that the UBASH3B 2HP domain represents a druggable interface for disrupting UBASH3B-dependent Aurora B regulation. We identify UBASHIN, a small-molecule inhibitor targeting this domain. UBASHIN phenocopies UBASH3B depletion, causing Aurora B mislocalization, mitotic arrest and mitotic cell death. UBASHIN impairs UBASH3B localization to the mitotic spindle and selectively inhibits cancer cell proliferation while sparing non-cancerous cells. UBASH3B protein levels and the cellular ability to sustain mitotic arrest, but not global aneuploidy, predict UBASHIN sensitivity, supporting a cancer-specific on-target mechanism. In colorectal and triple-negative breast cancer mouse models, UBASHIN reduces tumor volume comparably to docetaxel, without detectable toxicity in wild-type animals. These findings identify the UBASH3B pathway as a cancer-specific mitotic vulnerability and highlight its pharmacological inhibition as a selective therapeutic strategy.

31 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CKCeline Knorr
Celine Knorr
MZMehdi Zouiouich
Mehdi Zouiouich
JEJulie Eichler
Julie Eichler
MBMaxime Boutry
Maxime Boutry
CWCorinne Wendling
Corinne Wendling
FAFabien Alpy
Fabien Alpy
Membrane contact sites (MCSs) between the endoplasmic reticulum (ER) and other organelles or the plasma membrane play essential roles in lipid exchange and organelle homeostasis; however, how the molecular composition of these sites is functionally specified remains poorly understood. Here, we identify the ER-resident protein MOSPD2 as a novel regulator of late endosome/lysosome (LE/Lys) homeostasis and show that MOSPD2 selectively recruits the cholesterol transporter STARD3 at ER-LE/Lys contacts. Loss of either MOSPD2 or STARD3 leads to an expansion of the LE/Lys compartment, accumulation of free cholesterol at LE/Lys, and impaired LE/Lys fusion dynamics, indicating that both proteins act within a common pathway at ER-LE/Lys contact sites. STARD3 interacts with three members of the MSP-domain protein family, VAP-A, VAP-B and MOSPD2, yet, these tethers are not functionally equivalent at ER-LE/Lys MCSs. Using a series of quantitative binding assays, we show that STARD3 preferentially associates with MOSPD2 rather than with VAP-A or VAP-B, and that neither VAP-A nor VAP-B can compensate for the loss of MOSPD2 to restore LE/Lys biology and cholesterol distribution. This work establishes the MOSPD2-STARD3 complex as a unique functional unit that regulates LE/Lys homeostasis. Collectively, these findings reveal that selective pairing between MSP-domain proteins and their FFAT-containing partners exist and shape the interaction landscape of MCSs to define their functions.

11 February 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MZMehdi Zouiouich
Mehdi Zouiouich
TMThomas Di Mattia
Thomas Di Mattia
AMArthur Martinet
Arthur Martinet
JEJulie Eichler
Julie Eichler
CWCorinne Wendling
Corinne Wendling
FAFabien Alpy
Fabien Alpy
Membrane contact sites between organelles are organized by protein bridges. Among the components of these contacts, the VAP family comprises endoplasmic reticulum (ER)-anchored proteins, such as MOSPD2, functioning as major ER-organelle tethers. MOSPD2 distinguishes itself from the other members of the VAP family by the presence of a CRAL-TRIO domain. In this study, we show that MOSPD2 forms ER-LD contacts thanks to its CRAL-TRIO domain. MOSPD2 ensures the attachment of the ER to LDs through a direct protein-membrane interaction involving an amphipathic helix that has an affinity for lipid packing defects present at the surface of LDs. Remarkably, the absence of MOSPD2 markedly disturbs the assembly of lipid droplets. These data show that MOSPD2, in addition to being a general ER receptor for inter-organelle contacts, possesses an additional tethering activity and is specifically implicated in the biology of LDs via its CRAL-TRIO domain.